Drug name - Kazano

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2025

(2 years from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

CN1926128A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2011

(11 years ago)

CN102127057A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2013

(9 years ago)

CN102140090A TAKEDA PHARMS USA Dipeptidyl-Peptidase Inhibitor
Dec, 2013

(8 years ago)

CN102134230B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102134230A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102134231A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitor
Dec, 2024

(2 years from now)

CN102134229B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102134229A TAKEDA PHARMS USA Dipeptide Group Peptidase Inhibitor
Dec, 2024

(2 years from now)

CN102079743B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102079743A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitor
Dec, 2024

(2 years from now)

CN102134231B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

IN244233B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhbitors
Dec, 2024

(2 years from now)

EP1586571B1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571A1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571B3 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors Mar, 2025

(2 years from now)

US8900638 TAKEDA PHARMS USA Solid preparation comprising alogliptin and metformin hydrochloride May, 2029

(6 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE;1GM TABLET;ORAL Prescription
EQ 12.5MG BASE;500MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.